SGN-CEACAM5C

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameSGN-CEACAM5C
Drug Alias NameSGN-CEACAM5CPF-08046050SAR445953SAR-445953
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CEACAM5DNA topoisomerase I inhibitors
TargetsCarcinoembryonic antigen related cell adhesion molecule 5DNA topoisomerase I
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursSmall Cell Lung Carcinoma +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[8] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSeagen IncSanofi
China Registration ClassN/A

Develop Information

Active CompaniesPfizer (Beijing) Research and Development Co LtdSeagen IncSanofi +[4] 
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursSmall Cell Lung Carcinoma +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A